

11 MARCH 2021

LGP DELIVERS FIRST FRENCH SHIPMENT

COMPANY CONTINUES PUSH INTO KEY EUROPEAN GROWTH MARKETS

ASX ANNOUNCEMENT


Highlights:

-  Company delivers first shipment of medicinal cannabis oil to French national trial
-  Trial participation expected to bring significant first mover and reputational advantages in a potential future French medicinal cannabis market
-  LGP is one of only four international cannabis companies appointed as primary trial suppliers
-  Following shipment, LGP will have prescribed patients in each of the UK, Germany and France
-  Trial supply signifies LGP's commitment to key European markets, as Company begins ramping up growth of European teams

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to delivery of the first shipment of medicinal cannabis oils ("**Shipment**") into the French national medicinal cannabis trial ("**Trial**"). The Shipment is scheduled to be release tested in France and made available to Trial patients later this month.

The Company expects the Shipment of more than 4,800 units will help cement the Company's reputation for execution capability, with the medicines being produced under strict regulator-imposed timelines. At this time the Company cannot forecast final medicine quantities required as this will be driven by patient demand over the course of the Trial.





Trial background

In January, the Company was appointed as a primary medicinal cannabis oil supplier to the Trial in partnership with leading French pharmaceutical distributor, Intsel Chimos (see ASX announcement dated 27 January 2021). The Trial is being conducted by the French National Agency for the Safety of Medicines and Health Products (L'Agence nationale de sécurité médicamenteuse des produits de santé, or ANSM) and will be the only lawful source of cannabis medicines in France until the end of the Trial in early 2023. LGP is supplying cannabis medicines into the Trial alongside only three other primary suppliers, being global medicinal cannabis manufacturers Tilray, Panaxia, and Aurora.

First mover advantage

The Trial is anticipated to catalyse the legalisation of medicinal cannabis in France, which has an expected market value of €4 billion at maturity. LGP's appointment as a primary supplier into the Trial is anticipated to provide the Company with a significant first mover and reputational advantage in France and other key EU markets, including through brand-recognition and long-term key prescriber and patient familiarity. The Company is also negotiating the scope of its partnership with Intsel Chimos to support its post-Trial market growth in the territory and in other key markets.

Continued roll-out of pan-European strategy

Participating in the Trial as a primary supplier is in line with LGP's strategy of growing and holding significant market share in key European growth markets, including Germany, the UK, and France. To service these markets, the Company has commenced the deployment of specialist European personnel in the region, to provide enhanced local engagement capability.

The Company continues to navigate new pathways with leading distributors into other key markets in the region as well as develop new engagements within existing territories to help consolidate and further grow its market share.

ENDS



Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
T: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

